EN | UA
EN | UA

Help Support

Back

Real-world study of favipiravir to treat mild-to-moderate COVID-19

favipiravir favipiravir
favipiravir favipiravir

A multicentric, retrospective, single-arm study was conducted to assess the safety and efficacy of favipiravir (an RNA-dependent RNA polymerase inhibitor) in real-world clinical practice.

See All

Key take away

For treatment of mild to moderate COVID-19 patients, favipiravir exhibited a clinical resolution rate of >90%.

Background

A multicentric, retrospective, single-arm study was conducted to assess the safety and efficacy of favipiravir (an RNA-dependent RNA polymerase inhibitor) in real-world clinical practice.

Method

Examination of medical records was done to explore favipiravir's therapeutic benefit. A total of 360 people met inclusion criteria and 358 people (average age: 51.80 ± 16.45 years) were available for final analysis. Males made up 58.46% of the trial population.

Result

Myalgia-fatigue, fever, and cough were the most commonly encountered symptoms. The median time to fever relief and clinical cure was 4 and 5 days respectively. Average length of stay in hospital was found to be 6 days.  Side effects were experienced by 8% of subjects. Giddiness, fatigue, headache, decreased appetite, diarrhea, and hepatic enzyme elevation were the commonly noted symptoms.

Conclusion

The antiviral agent favipiravir exhibited a good clinical cure rate, and was well tolerated with few transient adverse events in coronavirus-infected people.  

Source:

Pragmatic and Observational Research

Article:

Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India

Authors:

Joshi S et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: